Leptin gene variants and colorectal cancer risk: Sex-specific associations

Kelsey A. Chun, Jonathan M. Kocarnik, Sheetal S. Hardikar, Jamaica R. Robinson, Sonja I. Berndt, Andrew T. Chan, Jane C. Figueiredo, Noralane M. Lindor, Mingyang Song, Robert E. Schoen, Richard B. Hayes, John D. Potter, Rami Nassir, Stéphane Bézieau, Loïc Le Marchand, Martha L. Slattery, Emily White, Ulrike Peters, Polly A. Newcomb

1 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America, 2 Institute of Translational Health Sciences, University of Washington, Seattle, WA, United States of America, 3 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States of America, 4 Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, MD, United States of America, 5 Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, United States of America, 6 Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States of America, 7 Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America, 8 Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, United States of America, 9 Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America, 10 Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America, 11 Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, PA, United States of America, 12 Division of Epidemiology, Department of Population Health, New York University School of Medicine, New York, NY, United States of America, 13 Department of Epidemiology, University of Washington, Seattle, WA, United States of America, 14 Department of Biochemistry and Molecular Medicine, University of California-Davis, Davis, CA, United States of America, 15 Service de Génétique Médicale, Université de Nantes, Nantes, France, 16 Epidemiology Program, University of Hawai’i Cancer Center, Honolulu, HI, United States of America, 17 Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT, United States of America

These authors contributed equally to this work.

kchun@fredhutch.org

Abstract

Background
High levels of serum leptin and low levels of serum adiponectin are strongly correlated with obesity, a well-established risk factor for colorectal cancer (CRC). Growing evidence suggests that dysregulation of leptin and adiponectin levels may play an etiological role in colorectal carcinogenesis. We evaluated 20 candidate variants in 4 genes previously shown to alter serum leptin and adiponectin levels for associations with obesity (BMI >30 kg/m²) and CRC risk.

Methods
We analyzed 6,246 CRC cases and 7,714 population-based controls from 11 studies within the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). Associations of each variant with obesity or CRC were evaluated using multivariate logistic regression models stratified by sex and adjusted for age, a study variable, and the first three principal
components of genetic ancestry. Gene-specific False Discovery Rate (FDR)-adjusted p-values <0.05 denoted statistical significance.

Results
Two variants in the leptin gene showed statistically significant associations with CRC among women: LEP rs2167270 (OR = 1.13, 95% CI: 1.06–1.21) and LEP rs4731426 (OR = 1.09, 95% CI: 1.02–1.17). These associations remained significant after adjustment for obesity, suggesting that leptin SNPs may influence CRC risk independent of obesity. We observed statistically significant interactions of the leptin variants with hormone replacement therapy (HRT) for CRC risk; these variant associations were strengthened when analyses were restricted to post-menopausal women with low estrogen exposure, as estimated by ‘never use’ of HRT and/or non-obese BMI. No variants were associated with CRC among men.

Conclusions
Leptin gene variants may exhibit sex-specific associations with CRC risk. Endogenous and exogenous estrogen exposure may modify the association between these variants, leptin levels, and CRC risk.

Introduction
Both high levels of serum leptin and low levels of serum adiponectin are strongly correlated with obesity [1, 2], which is a well-established risk factor for colorectal cancer (CRC) [3]. Whether there is a direct relationship between aberrant leptin and adiponectin levels and CRC independent of obesity, however, is not well characterized. Previous evidence suggests that leptin and adiponectin—two adipocyte-derived hormones that are involved in the regulation of energy homeostasis and insulin sensitivity [4]—may influence the colorectal carcinogenic pathway in opposing ways. Leptin has been shown to act as a growth factor in colonic epithelial cells, promoting tumor cell proliferation and migration and suppressing apoptosis [5]. Adiponectin, by contrast, has been shown to exert an anti-tumorigenic effect by inhibiting cancer cell growth and inducing apoptosis [6].

Epidemiological studies have yielded inconsistent findings on the relationship between adipokine levels and CRC. Several studies have found higher serum leptin [7, 8] and lower serum adiponectin [9–11] levels to be associated with elevated CRC risk, while other studies report conflicting [12–14] or null [15, 16] associations. In addition, several studies have reported that the relationship between adipokine levels and CRC varies by sex [17–21], with stronger positive associations reported in males. Genetic variation in the genes encoding these hormones, or their hormone receptors, may contribute to these differential associations. Greater insight into the role of leptin and adiponectin gene variants in colorectal carcinogenic pathways may therefore contribute to our understanding of the genetic basis of CRC risk.

This study investigated the potential role of candidate gene variants of leptin and adiponectin in sex-specific pathways of obesity and colorectal carcinogenesis. A literature search for variants reported to alter circulating leptin or adiponectin levels identified 20 variants in the genes encoding leptin, adiponectin, and their respective receptors. Associations between these variants with obesity and CRC risk were evaluated using the large data resources of the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) [22, 23].
Materials and methods

Variant selection

A literature search in the PubMed database identified studies that characterized the association between gene variants in leptin (LEP), leptin receptor (LEPR), adiponectin (ADIPOQ), or adiponectin receptor (ADIPOR1) and serum levels of leptin or adiponectin. Variants previously reported as significantly associated with serum leptin or adiponectin levels in at least one prior study were included in our analysis [24–38]. Variants reported as significant predictors of CRC in at least one prior study were included, regardless of whether the gene variants had also been linked to serum hormone levels [39–47]. In total, this literature search identified 20 variants across these four genes: 3 in LEP, 3 in LEPR, 11 in ADIPOQ, and 3 in ADIPOR1.

Study population

This analysis utilized 6,246 CRC cases (4,996 colon cancer, 1,108 rectal cancer) and 7,714 population-based controls pooled from 11 epidemiologic studies within GECCO. This included: the French Association Study Evaluating RISK for sporadic colorectal cancer (ASTERISK); Hawaii Colorectal Cancer Studies 2&3 (Colo2&3); Diet, Activity, and Lifestyle Study (DALS); Health Professionals Follow-up Study (HPFS); Multiethnic Cohort (MEC); Nurses’ Health Study (NHS); Physician’s Health Study (PHS); Prostate, Lung, Colorectal Cancer, and Ovarian Cancer Screening Trial (PLCO); Postmenopausal Hormone Study (PMH); VITamins And Lifestyle (VITAL); and Women’s Health Initiative (WHI). Study design and inclusion details regarding individual studies within GECCO have been previously described [22, 23]. Colorectal cancer cases were previously defined by GECCO via ICD-9 codes as stage 1–4 colorectal adenocarcinoma. Obesity was defined as body mass index (BMI) \( \geq 30 \text{ kg/m}^2 \), consistent with the World Health Organization (WHO) definition [48].

Genotyping and imputation

We used existing genotype data from prior genome-wide association studies (GWAS) performed in GECCO, the details of which have been previously described [22, 23]. Briefly, genotyping and quality control were performed using a standard process that excluded variants that did not meet quality control measures for Hardy-Weinberg Equilibrium in controls (HWE \( p < 10^{-4} \)) or low call rate (\(<98\% \)). To increase coverage, genotypes were imputed to the Haplotype Reference Consortium (version 1) [49], excluding variants that had a low minor allele count (MAC \(< 5 \)) or poor imputation accuracy (\( R^2 < 0.3 \)).

Statistical analysis

For each candidate variant, we examined the association with obesity and CRC risk. We calculated odds ratios (ORs) and 95% confidence intervals (95% CI) using multivariate logistic regression, with models stratified by sex and adjusted for age, a study variable that accounts for genotyping platform, and the first three principal components of genetic ancestry [50]. Sensitivity analyses conducted for variant associations with CRC were additionally adjusted for obesity (obese/non-obese BMI). ORs refer to the risk per coded allele. Sex-stratified analyses were conducted based upon previous evidence of the sex-dependent nature of relationships between obesity and CRC risk [51], serum leptin and colorectal adenoma risk [17], and serum adiponectin and CRC risk [18].

To account for multiple comparisons, False Discovery Rate (FDR)-adjusted \( p \)-values were calculated for variants within sex and within each gene or receptor, with \( p_{\text{FDR}} < 0.05 \) considered statistically significant [52]. Wald tests evaluated potential gene-gene and gene-
environment interactions. All statistical tests and p-values were two-sided. All analyses were performed using STATA version 14.0 (StataCorp, College Station, TX).

**Ethics statement**

This study was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

**Results**

Selected characteristics of the studies and participants included in our analysis are described in Tables 1 and S1. The mean age of study participants across 11 studies was 63.8 years old, and mean BMI was 26.9 kg/m^2.

Table 2 describes the candidate SNPs in leptin, adiponectin, and their receptors and summarizes their associations with CRC risk. Two variants in leptin were positively associated with CRC risk among women: \( LEP \) rs2167270 (OR = 1.13, 95% CI: 1.06–1.21, \( p_{FDR} = 0.003 \) ) and \( LEP \) rs4731426 (OR = 1.09, 95% CI: 1.02–1.17, \( p_{FDR} = 0.005 \) ). None of the 20 candidate variants, however, was statistically significantly associated with CRC risk among men. Testing the interaction between these variants and sex initially suggested a difference in CRC risk by sex for \( LEP \) variant rs4731426 (\( p = 0.06 \)) but was not significant after FDR adjustment (\( p_{FDR} = 0.18 \)). Testing for variant associations under dominant or recessive genetic models did not substantially alter our results.

The two leptin gene variants associated with CRC risk in women were not concomitantly associated with obesity (\( p = 1.00 \)). To assess whether obesity was confounding the association between leptin variants and CRC in women, we adjusted our initial logistic regression model for obesity (obese/non-obese BMI). The associations of \( LEP \) variants rs2167270 and rs4731426 with CRC risk remained statistically significant after this adjustment (\( p_{FDR} \leq 0.03 \)).

Based on prior studies of sex hormones in relation to leptin levels, as well as CRC risk, we performed stratified analyses according to exogenous estrogen exposure and assessed potential gene-environment interactions between the leptin variants and estrogen exposure with regards to CRC risk among women.

Among post-menopausal women, we observed that the associations of \( LEP \) rs2167270 and rs4731426 with CRC varied according to history of estrogen-only (EO) hormone replacement therapy (HRT) use, categorically defined as 0 years (Never users), <10 years, and \( \geq 10 \) years \( (p_{FDR} \text{ for interaction: } 0.02 \text{ and } 0.02, \text{ respectively}) \). We then conducted stratified analyses in post-menopausal women according to history of EO HRT (Table 3). The associations of \( LEP \) rs2167270 and rs4731426 were non-significant in both categories of EO HRT ever users. In never users, however, the variants were statistically significantly associated with CRC risk, and their effect sizes were strengthened \( (LEP \text{ rs2167270: OR } = 1.54, 95\% \text{ CI: } 1.19–1.99, p_{FDR} = 0.003; \text{ LEP \text{ rs4731426: OR } = 1.37, 95\% \text{ CI: } 1.08–1.74, p_{FDR} = 0.03}) \) \( (p_{FDR} \text{ for interaction: } 0.02 \text{ and } 0.02, \text{ respectively}) \).

Given that the associations of leptin variants with CRC were strengthened when analyses were restricted to women with lower exogenous estrogen exposure, as estimated by never EO HRT use, we attempted to assess whether the trend would persist in women with lower endogenous estrogen exposure, using menopausal status and obesity status as proxies. Although no statistically significant interaction effects were observed between the two leptin gene variants and menopausal status or obesity status, in analyses stratified by menopausal status, associations of leptin variants with CRC risk remained statistically significant only among post-menopausal women. In analyses of post-menopausal women stratified by obese versus non-obese BMI, associations of the two leptin variants with CRC remained statistically significant in non-
obese women only (Table 4). Among men and pre-menopausal women, analyses stratified by obese versus non-obese BMI did not yield any statistically significant SNP associations. Consistent with these observations, the CRC risk conferred by \textit{LEP} variants rs2167270 and rs4731426 was highest among women who fulfilled all three categories of low estrogen exposure: non-obese, post-menopausal, never users of EO HRT (\textit{LEP} rs2167270: OR = 1.69, 95% CI: 1.26–2.26, \textit{p} _{FDR} = 0.003; \textit{LEP} rs4731426: OR = 1.49, 95% CI: 1.13–1.96, \textit{p} _{FDR} = 0.003). These results suggest that estrogen exposure–both exogenous and endogenous–may modify the association between leptin gene variants and CRC risk.

Table 1. Demographic and baseline characteristics of colorectal cancer cases and controls.

|                     | Cases N = 6,246 | Controls N = 7,714 |
|---------------------|----------------|-------------------|
| **Age, years**      |                |                   |
| Under 50            | 112 (3)        | 172 (6)           |
| 50–59               | 728 (20)       | 559 (21)          |
| 60–69               | 1,635 (46)     | 1,106 (42)        |
| 70–79               | 1,047 (29)     | 761 (29)          |
| 80+                 | 69 (2)         | 57 (2)            |
| **BMI, kg/m$^2$**   |                |                   |
| Underweight, <18.5  | 31 (1)         | 7 (0)             |
| Normal, 18.5–24.9   | 1,192 (33)     | 654 (25)          |
| Overweight, 25.0–29.9 | 1,105 (31) | 984 (37)          |
| Obese Class I, 30.0–34.9 | 561 (16) | 330 (12)          |
| Obese Class II, 35.0–39.9 | 204 (6) | 79 (3)            |
| Obese Class III, ≥ 40.0 | 112 (3) | 30 (1)            |
| **Postmenopausal**  |                |                   |
| Yes                 | 3,419 (95)     | 4,246 (92)        |
| No                  | 151 (4)        | 385 (8)           |
| **HRT use at baseline** |            |                   |
| Yes                 | 1,119 (31)     | 1,870 (48)        |
| No                  | 1,916 (53)     | 2,054 (52)        |
| **EO HRT use at baseline** |        |                   |
| Yes                 | 470 (13)       | 941 (20)          |
| No                  | 1,680 (47)     | 2,117 (46)        |
| **Duration of EO HRT use** |        |                   |
| 0 years (Never users) | 211 (6)  | 787 (17)          |
| >10 years           | 446 (12)       | 684 (15)          |
| ≥10 years           | 270 (8)        | 464 (10)          |
| **Stage at Diagnosis** |            |                   |
| Stage 1 or local    | 1,127 (27)     | 800 (27)          |
| Stage 2/3 or regional| 1,849 (45) | 1,301 (44)        |
| Stage 4 or distant  | 420 (10)       | 274 (9)           |
| **Tumor Site**      |                |                   |
| Colon               | 2,863 (80)     | 2,098 (79)        |
| Rectum              | 599 (17)       | 501 (19)          |

BMI = Body Mass Index; HRT = Hormone Replacement Therapy; EO = Estrogen-Only
* Do not sum to total due to missing values

https://doi.org/10.1371/journal.pone.0206519.1001
To examine whether other forms of HRT would have a similar impact on the association of leptin variants with CRC risk, we performed stratified analyses according to estrogen-progesterone (EP) HRT. Unlike with EO HRT use at baseline, associations of leptin variants with CRC risk were statistically significant among both users and non-users of EP HRT at baseline, and the association of both variants with CRC risk was only borderline significant among never users. Overall, EP HRT use did not appear to modify SNP effects as strikingly as EO HRT use.

Given evidence in prior studies that obesity is more strongly associated with colon rather than rectal cancer [53], we assessed associations of SNPs with CRC in analyses stratified by

| Gene | Variant | CA/RA | CAF | OR (95% CI) | p   | OR (95% CI) | p   |
|------|---------|-------|-----|-------------|-----|-------------|-----|
| LEP  | rs2167270 | G/A   | 0.63 | 1.13 (1.06–1.21) | <0.001* | 0.96 (0.89–1.04) | 0.36 |
|      | rs7799039 | A/G   | 0.45 | 1.06 (0.99–1.13) | 0.08 | 0.99 (0.92–1.07) | 0.86 |
|      | rs4731426 | C/G   | 0.56 | 1.09 (1.02–1.17) | 0.008* | 0.99 (0.92–1.07) | 0.88 |
| LEPR | rs1137101 | G/A   | 0.45 | 0.99 (0.92–1.05) | 0.66 | 0.98 (0.91–1.06) | 0.66 |
|      | rs6588147 | A/G   | 0.68 | 1.01 (0.94–1.08) | 0.78 | 1.04 (0.96–1.13) | 0.35 |
| ADIPO1| rs1342387 | C/T   | 0.54 | 0.99 (0.93–1.06) | 0.82 | 0.99 (0.91–1.06) | 0.72 |
|      | rs12733285 | T/C   | 0.31 | 1.03 (0.96–1.11) | 0.47 | 0.98 (0.90–1.07) | 0.69 |
| ADIPOQ | rs7539542 | C/G   | 0.69 | 0.98 (0.91–1.06) | 0.67 | 1.00 (0.92–1.09) | 0.98 |
|      | rs1501299 | T/G   | 0.28 | 0.96 (0.89–1.03) | 0.23 | 1.00 (0.92–1.09) | 0.95 |
|      | rs17366743 | C/T   | 0.03 | 1.00 (0.81–1.25) | 0.96 | 1.05 (0.82–1.35) | 0.70 |
|      | rs16861194 | G/A   | 0.08 | 0.99 (0.87–1.13) | 0.90 | 0.95 (0.82–1.10) | 0.47 |
|      | rs2241766 | C/T   | 0.11 | 0.97 (0.87–1.07) | 0.55 | 1.01 (0.89–1.13) | 0.93 |
|      | rs17300539 | T/C   | 0.09 | 0.86 (0.76–0.98) | 0.03 | 0.99 (0.85–1.14) | 0.85 |
|      | rs822387 | C/G   | 0.09 | 0.90 (0.79–1.02) | 0.11 | 1.00 (0.86–1.15) | 0.97 |
|      | rs12495941 | T/G   | 0.35 | 0.98 (0.91–1.05) | 0.56 | 1.01 (0.93–1.10) | 0.77 |
|      | rs182052 | A/G   | 0.34 | 0.98 (0.91–1.05) | 0.51 | 0.96 (0.88–1.04) | 0.35 |
|      | rs822396 | A/G   | 0.81 | 0.96 (0.88–1.04) | 0.34 | 1.02 (0.92–1.12) | 0.72 |
| ADIPOQ | rs822395 | A/C   | 0.65 | 1.00 (0.93–1.07) | 0.94 | 1.03 (0.95–1.12) | 0.47 |
|      | rs1063538 | C/T   | 0.61 | 1.06 (0.99–1.13) | 0.10 | 1.00 (0.92–1.08) | 0.95 |

CA = Coded Allele; RA = Reference Allele; CAF = Coded Allele Frequency; OR = Odds Ratio per coded allele; CI = Confidence Interval

Adjusted for age, study, and first three principal components of genetic ancestry

* p<0.05 after FDR-adjustment

https://doi.org/10.1371/journal.pone.0206519.t002

Table 3. Associations of candidate leptin variants with colorectal cancer among post-menopausal women, by duration of estrogen-only hormone replacement therapy use.

| Gene | Variant |  >10 years (N = 696) |  <10 years (N = 998) |  0 years (N = 685) |
|------|---------|---------------------|---------------------|---------------------|
|      | OR (95% CI) | p   | OR (95% CI) | p   | OR (95% CI) | p   |
| LEP  | rs2167270 | 0.97 (0.76–1.13) | 0.07 | 1.06 (0.88–1.29) | 0.53 | 1.54 (1.19–1.99) | 0.001* |
|      | rs7799039 | 0.81 (0.65–1.02) | 0.07 | 1.05 (0.88–1.26) | 0.58 | 1.37 (1.08–1.74) | 0.01* |
|      | rs4731426 | 0.96 (0.76–1.20) | 0.07 | 1.01 (0.84–1.22) | 0.89 | 1.37 (1.08–1.74) | 0.01* |

EO = Estrogen-Only; HRT = Hormone Replacement Therapy; OR = Odds Ratio per coded allele; CI = Confidence Interval

Adjusted for age, study, and first three principal components of genetic ancestry

* p<0.05 after FDR-adjustment

https://doi.org/10.1371/journal.pone.0206519.t003
subsite. However, no subsite-specific associations were statistically significant in analyses stratified by sex or across the total study population.

We also assessed potential gene-gene interactions between leptin and adiponectin variants with regards to CRC risk. Previous studies have posited that the ratio of circulating leptin to adiponectin levels may be a more salient marker of disease risk than leptin or adiponectin levels alone [19, 54]. Therefore, we hypothesized that the interaction of leptin and adiponectin variants might confer multiplicative CRC risk. However, modeling pairwise interactions between \textit{LEP} and \textit{ADIPOQ} variants for CRC risk did not identify any statistically significant interactions in sex-stratified analyses.

Although not the primary focus on our analyses, we also identified two variants significantly associated with obesity risk (S2 Table). As with the CRC associations, both associations with obesity were sex-specific. \textit{LEPR} rs6588147 was associated with obesity among women (OR = 1.12, 95% CI: 1.03–1.22) but not among men. By contrast, \textit{ADIPOQ} rs17366743 was associated with obesity among men (OR = 0.52, 95% CI: 0.34–0.79) but not among women.

\section*{Discussion}

We found evidence for several sex-specific genetic associations with obesity and CRC risk. Two variants in the leptin gene (rs2167270 and rs4731426) were associated with increased CRC risk in women but not in men, and were not concomitantly associated with obesity. These associations remained statistically significant after adjustment for BMI, suggesting that these leptin variants may be associated with colorectal carcinogenesis independently of obesity.

Prior studies have reported associations of intronic variant rs4731426 and exonic variant rs2167270 with circulating leptin levels, suggesting that these SNPs are functional. Dasgupta et al. reported an increasing trend in leptin levels for each addition of the C minor allele in \textit{LEP} rs4731426 [24]. Consistent with this finding, our study observed that the C allele of this variant was associated a modest increased risk of CRC among women.

Prior findings regarding \textit{LEP} rs2167270 in relation to leptin levels and CRC risk have been conflicting. Some studies have observed associations of the A allele of \textit{LEP} rs2167270 –the reference allele in our study–with elevated leptin levels [24, 55]. Contradictory to what we would then expect given the proposed directional effect, several studies have reported significant association of the A allele of this variant with decreased CRC risk [39, 40]. Consistent with these observations, our study observed that the G allele of this variant was associated with a modest increased CRC risk among women.

Linkage disequilibrium analysis of variants rs2167270 and rs4731426 revealed that the G allele and C allele of each variant, respectively, are highly correlated. We therefore matched the

| Gene | Variant | Obese \(N = 1,599\) | Non-obese \(N = 4,886\) |
|------|---------|----------------|------------------|
| \textit{LEP} | rs2167270 | 1.00 (0.86–1.16) | 0.99 | 1.18 (1.08–1.29) | <0.001* |
| \textit{LEP} | rs7799039 | 0.97 (0.84–1.12) | 0.69 | 1.06 (0.98–1.15) | 0.15 |
| \textit{LEP} | rs4731426 | 0.96 (0.83–1.11) | 0.60 | 1.13 (1.04–1.23) | 0.003* |

\(OR = \text{Odds Ratio per coded allele; CI = Confidence Interval}\)

\(*p<0.05\) after FDR-adjustment

https://doi.org/10.1371/journal.pone.0206519.t004

https://doi.org/10.1371/journal.pone.0206519.0004
reference and coded alleles for LEP rs2167270 and rs4731426 to reflect this correlation. In our study, the correlation coefficient between coded alleles of leptin variants rs2167270 and rs4731426 was 0.85. Within NCI LDmatrix (https://analysistools.nci.nih.gov/LDlink/), the variants were found to have an $r^2$ value of 0.72.

To our knowledge, ours is the first study to report sex-specific associations between leptin variants and CRC risk among women but not among men. Prior reports of sex differences in the association between adipokine levels and risk for colorectal neoplasia have found leptin and adiponectin levels to be more predictive of risk among men than among women [17–20]. Previously, Chia et al. reported a three-fold increased risk of colorectal adenoma for the highest versus lowest quartile of leptin among men, but found no association among women [17]. Yamaji et al. reported a 40% reduced risk of colorectal adenoma for the highest versus lowest tertile of adiponectin among men, but not among women [19]. Similarly, Song et al. reported a 45% lower risk of CRC for the highest versus lowest quartile of adiponectin among men, but no association among women [18].

Each of these studies' analyses adjusted for important confounders, including BMI, waist circumference, or some other covariate associated with obesity, and found that their results remained statistically significant. The mechanisms underlying the heterogeneity by sex observed in these studies were unclear, though the authors proposed several hypotheses. One explanation was that sex differences in adipokine levels—in particular, higher levels of both adiponectin and leptin among women compared to men—contributed to the null finding in women [18]. Another explanation was that sex differences in body fat distribution may affect leptin levels and their observed effect on CRC risk [56].

Studies reporting sex differences in the associations between gene variants in leptin and adiponectin and CRC have been similarly limited to findings in men. A study by Partida-Perez et al. found that LEP rs2167270 was associated with CRC risk among men but not among women [57]. Slattery et al. reported a sex-specific association in leptin receptor, finding that LEPR rs6588147 was associated with increased risk of colon cancer among men but not among women [39].

Our finding on the relationship between leptin variants and CRC risk among women raises new questions regarding the mechanisms by which leptin and leptin gene variants might affect colorectal carcinogenic pathways. Given the interactions we observed between these variants and other factors, we propose mechanisms that may be independent of obesity.

We observed that associations of LEP rs2167270 and rs4731426 with CRC risk among women remained significant, and were strengthened, when analyses were restricted to women with low exogenous and endogenous estrogen exposure. The risk conferred by these leptin variants was highest among women who were post-menopausal, non-obese, and had no prior history of EO HRT use. These results suggest that estrogen exposure may modify the association between leptin gene variants and CRC risk. Specifically, estrogen exposure may be protective against the risk conferred by functional leptin variants, such that these variants only exert a detectable effect among women with low lifetime estrogen exposure. The mechanisms underlying this relationship in the context of our study remain unclear. However, prior studies have found suggestive evidence that sex-specific associations between leptin levels and CRC risk may involve functional cross-talk between leptin and estrogen systems [58].

Colorectal cancer incidence is lower among women compared with men, and it has been hypothesized that female hormones may play a protective role [59]. The protective effects of estrogen are believed to be mediated by ERβ—the predominant estrogen receptor in human colon [60]. ERβ expression is markedly and selectively reduced in CRC tissue compared to normal adjacent tissue [60], and inversely associated with stage of colorectal cancer and prognosis [61]. Silencing of ERβ by genetic knockdown or promoter methylation has been
previously shown to induce aberrant cell proliferation while upregulation of ERβ has been shown to promote apoptotic signaling, suggestive of ERβ's role as a tumor suppressor [62].

Leptin, by contrast, has been previously shown to act as a growth factor in colon epithelial cells. Binding of leptin to its receptor activates transcription (JAK/STAT) and Ras/extracellular signal-regulated kinase (ERK1/2) signal transduction pathways [63], inducing tumor cell proliferation and migration and suppressing apoptosis. Interestingly, evidence from prior studies suggests functional crosstalk between estrogen and leptin, with estrogen opposing the oncogenic effects of leptin. In adipocytes, estrogen (E2) administration has been shown to increase ERβ expression and subsequently reduce leptin expression [58]. In hepatic cells, E2 administration has been shown to inhibit leptin-stimulated cell growth (via decreased STAT3 signaling) and enhanced leptin-suppressed apoptosis (via increased SOCS3 signaling) through activation of ERβ [64]. These experimental findings support the results of our study, and taken together, suggest that estrogen exposure may be protective against the oncogenic effects of leptin variants associated with elevated circulating leptin levels.

In addition, that EO but not EP HRT use appeared to be strongly protective against leptin SNP-associated CRC risk in our study aligns with prior evidence for repression of estrogen-stimulated ER activity by liganded progestin receptor [65].

Our results may also shed light on a somewhat controversial hypothesis regarding obesity and CRC in post-menopausal women: that elevated endogenous estrogen in overweight and obese women—specifically postmenopausal women—may attenuate obesity-associated CRC risk [66, 67]. The relationship between obesity and CRC is known to be stronger in men compared in women, and when women are further stratified by menopausal status, the attenuated relationship between obesity and CRC risk is clearly restricted to postmenopausal women [68, 69]. Given the suggested protective effects of estrogen exposure among women and the fact that adipose tissue is the primary source of endogenous estrogen in postmenopausal women, it has been hypothesized that increased adiposity is less pathogenic in postmenopausal women than in their male and premenopausal counterparts. In our study, stratified analyses by obese versus non-obese BMI among postmenopausal women revealed that the CRC risk conferred by LEP SNPs was restricted to non-obese women. There was no evidence of leptin-associated CRC risk in the post-menopausal obese women, which may suggest that adiposity in postmenopausal women may confer some protective against the effects of leptin variants or elevated leptin levels.

A key strength of this study is its large sample size, leveraging nearly 14,000 CRC cases and controls pooled from 11 different studies. Although we selected variants that were functionally associated with protein expression, we nonetheless did not directly measure circulating leptin or adiponectin. In addition, our measures for estimating endogenous estrogen using menopausal status and obesity are only approximations. Despite the study’s limitations, we believe the results provide compelling suggestive evidence for the role of estrogen in modifying the carcinogenic effects of leptin. To our knowledge, this is the first study to report on estrogen as an effect modifier of leptin in an epidemiologic setting.

Validation studies evaluating our sex-specific genetic findings for CRC risk with directly measured serum levels of leptin, estrone, and estradiol would be very informative. Future studies should also be directed towards discerning the functional roles of these two leptin variants, which still remain largely unclear. Although candidate SNPs were selected for this study based on previously reported association with leptin levels, more direct laboratory investigation of these variants is still needed. To our knowledge, no experimental studies have adequately assessed the functional role of these variants beyond their correlation with leptin levels.

In conclusion, our study investigated the role of leptin and adiponectin in obesity and colorectal cancer using a candidate gene variant approach. Analyses revealed statistically
significant sex-specific associations between two leptin gene variants—LEP rs2167270 and LEP rs4731426—and CRC risk among women but not men. These gene variants in leptin were not associated with obesity risk among women and remained significantly associated with CRC after adjustment for obese vs non-obese BMI. In addition, these associations were strengthened when analyses were restricted to women with low estrogen exposure, as estimated by post-menopausal status, never use of hormone replacement therapy, and non-obese BMI. These results suggest that estrogen exposure may modify the association between leptin gene variants and CRC risk.

Supporting information
S1 Table. Characteristics of study participants across 11 studies in the Genetic Epidemiology of Colorectal Cancer Consortium (GECCO).

S2 Table. Associations of candidate genetic variants with obesity.

Acknowledgments
GECCO: The authors would like to thank all those at the GECCO Coordinating Center for helping bring together the data and people that made this project possible. The authors also acknowledge Deanna Stelling, Mark Thornquist, Greg Warnick, Carolyn Hutter, and team members at COMPASS (Comprehensive Center for the Advancement of Scientific Strategies) at the Fred Hutchinson Cancer Research Center for their work harmonizing the GECCO epidemiological data set. The authors acknowledge Dave Duggan and team members at TGEN (Translational Genomics Research Institute), the Broad Institute, and the Genome Québec Innovation Center for genotyping DNA samples of cases and controls, and for scientific input for GECCO.

ASTERISK: We are very grateful to Dr. Bruno Buecher without whom this project would not have existed. We also thank all those who agreed to participate in this study, including the patients and the healthy control persons, as well as all the physicians, technicians and students.

HPFS, NHS and PHS: We would like to acknowledge Patrice Soule and Hardeep Ranu of the Dana Farber Harvard Cancer Center High-Throughput Polymorphism Core who assisted in the genotyping for NHS, HPFS, and PHS under the supervision of Dr. Immaculata Devivo and Dr. David Hunter, Qin (Carolyn) Guo and Lixue Zhu who assisted in programming for NHS and HPFS, and Haiyan Zhang who assisted in programming for the PHS. We would like to thank the participants and staff of the Nurses’ Health Study and the Health Professionals Follow-Up Study, for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

PLCO: The authors thank Drs. Christine Berg and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Center investigators and staff or the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Mr. Tom Riley and staff, Information Management Services, Inc., Ms. Barbara O’Brien and staff, Westat, Inc., and Drs. Bill Kopp and staff, SAIC-Frederick. Most importantly, we acknowledge the study participants for their contributions to making this study possible. The statements contained herein are solely those of the authors and do not represent or imply concurrence or endorsement by NCI.
PMH: The authors would like to thank the study participants and staff of the Hormones and Colon Cancer study.

WHI: The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whi.org/researchers/Documents%20Write%20a%20Paper/WHI%20Investigator%20Short%20List.pdf

Author Contributions

Conceptualization: Kelsey A. Chun, Mingyang Song.

Data curation: Kelsey A. Chun.

Formal analysis: Kelsey A. Chun.

Funding acquisition: Jonathan M. Kocarnik, Ulrike Peters, Polly A. Newcomb.

Methodology: Kelsey A. Chun, Jonathan M. Kocarnik, Sheetal S. Hardikar, Jamaica R. Robinson, Polly A. Newcomb.

Supervision: Jonathan M. Kocarnik, Polly A. Newcomb.

Writing – original draft: Kelsey A. Chun.

Writing – review & editing: Kelsey A. Chun, Jonathan M. Kocarnik, Sheetal S. Hardikar, Jamaica R. Robinson, Sonja I. Berndt, Andrew T. Chan, Jane C. Figueiredo, Noralane M. Lindor, Mingyang Song, Robert E. Schoen, Richard B. Hayes, John D. Potter, Rami Nassir, Stéphane Bézieau, Loïc Le Marchand, Martha L. Slattery, Emily White, Ulrike Peters, Polly A. Newcomb.

References

1. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochemical and biophysical research communications. 2012; 425(3):560–4. Epub 2012/08/29. https://doi.org/10.1016/j.bbrc.2012.08.024 PMID: 22926674.

2. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. European journal of endocrinology. 2002; 147(2):173–80. Epub 2002/08/03. PMID: 12153737.

3. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007; 16(12):2533–47. https://doi.org/10.1158/1055-9965.EPI-07-0708 PMID: 18089756.

4. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004; 53 Suppl 1:S143–51. Epub 2004/01/30. PMID: 14749280.

5. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001; 121(1):79–90. Epub 2001/07/05. PMID: 11438496.

6. Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Molecular endocrinology (Baltimore, Md). 2010; 24(7):1441–52. Epub 2010/05/07. https://doi.org/10.1210/me.2009-0498 PMID: 20444885.

7. Tamakoshi K, Toyoshima H, Wakai K, Kojima M, Suzuki K, Watanabe Y, et al. Leptin Is Associated with an Increased Female Colorectal Cancer Risk: A Nested Case-Control Study in Japan. Oncology. 2005; 68(4–6):454–61. https://doi.org/10.1159/000086986 PMID: 16020976

8. Wang D, Gao L, Gong K, Chai Q, Wang G. Increased serum leptin level in overweight patients with colon carcinoma: A cross-sectional and prospective study. Molecular and clinical oncology. 2017; 6(1):75–8. Epub 2017/01/27. https://doi.org/10.3892/mco.2016.1087 PMID: 28123733.

9. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. Journal of the National Cancer Institute. 2005; 97(22):1688–94. Epub 2005/11/17. https://doi.org/10.1093/jnci/dij376 PMID: 16288122.
10. Gialamas SP, Petridou ET, Tseleni-Balafouta S, Spyridopoulos TN, Matsoukis IL, Kondi-Pafi A, et al. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism: clinical and experimental. 2011; 60(11):1530–8. Epub 2011/06/03. https://doi.org/10.1016/j.metabol.2011.03.020 PMID: 21632074.

11. Tae CH, Kim SE, Jung SA, Joo YH, Shim KN, Jung HK, et al. Involvement of adiponectin in early stage of colorectal carcinogenesis. BMC cancer. 2014; 14:811. Epub 2014/11/06. https://doi.org/10.1186/1471-2407-14-811 PMID: 25370174; PubMed Central PMCID: PMC4326555.

12. Arpaci F, Yilmaz MI, Ozet A, Ayta H, Ozturk B, Komurcu S, et al. Low serum leptin level in colon cancer patients without significant weight loss. Tumori. 2002; 88(2):147–9. Epub 2002/06/29. PMID: 12086256.

13. Joshi RK, Kim WJ, Lee S-A. Association between obesity-related adipokines and colorectal cancer: A case-control study and meta-analysis. World Journal of Gastroenterology. WJG. 2014; 20(24):7941–9. https://doi.org/10.3748/wjg.v20.i24.7941 PubMed PMID: PMC4069321. PMID: 24976730.

14. Kuram A, Daniel P, Pietruczuk M, Malecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. International journal of colorectal disease. 2009; 24(3):275–81. Epub 2008/11/04. https://doi.org/10.1007/s00384-008-0605-y PMID: 18979105.

15. Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15(2):401–2. Epub 2006/02/24. https://doi.org/10.1158/1055-9965.EPI-05-0836 PMID: 16492937.

16. Aleksandrova K, Boeing H, Jenab M, Bueno-de-Mesquita HB, Jansen E, van Duin nhoven FJ, et al. Leptin and soluble leptin receptor in risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Cancer Res. 2012; 72(20):5328–37. Epub 2012/08/29. https://doi.org/10.1158/0008-5472.CAN-12-0465 PMID: 22926557.

17. Chia VM, Newcomb PA, Lampe JW, White E, Mandelson MT, McTiernan A, et al. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2007; 16(12):2697–703. https://doi.org/10.1158/1055-9965.EPI-07-0467 PMID: 18066776.

18. Song M, Zhang X, Wu K, Ogino S, Giovannucci EL, et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res (Phila). 2011; 3(6):875–85. Epub 2010/07/23. https://doi.org/10.1158/1940-6207.capr-10-0169 PMID: 23872505; PubMed Central PMCID: PMC3772620.

19. Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between Adiponectin and Leptin Influences the Risk of Colorectal Adenoma. Cancer Research. 2010; 70(13):5430. https://doi.org/10.1158/0008-5472.CAN-10-0178 PMID: 20516125.

20. Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. Journal of digestive diseases. 2011; 12(4):234–44. Epub 2011/07/28. https://doi.org/10.1111/j.1751-2980.2011.00504.x PMID: 21791018.

21. Stattin P, Palmqvist R, Soderberg S, Biessy C, Ardnor B, Hallmans G, et al. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncology reports. 2003; 16(6):2015–21. Epub 2003/10/10. PMID: 14534736.

22. Peters U, Hutter CM, Hsu L, Schumacher FR, Conti DV, Carlson CS, et al. Meta-analysis of new genome-wide association studies of colorectal cancer risk. Human genetics. 2012; 131(2):217–34. Epub 2012/08/29. https://doi.org/10.1007/s00439-011-1055-0 PMID: 22730693; PubMed Central PMCID: PMC3257356.

23. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, et al. Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology. 2013; 144(4):799–807 e24. Epub 2012/12/26. https://doi.org/10.1053/j.gastro.2012.12.020 PMID: 23266556; PubMed Central PMCID: PMC3636812.

24. Dasgupta S, Salman M, Siddalingaiah LB, Lakshmi GL, Xaviour D, Sreenath J. Genetic variants in leptin: Determinants of obesity and leptin levels in South Indian population. Adipocyte. 2015; 4(2):315–20. Epub 2015/09/04. PMID: 26333998.

25. Hofstede J, Eriksson P, Mottagui-Tabar S, Arner P. A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Hormone and metabolic research = Hormon- und Stoffwechselfor schung = Hormones et metabolisme. 2002; 34(7):355–9. Epub 2002/08/22. https://doi.org/10.1055/s-2002-33466 PMID: 12189581.

26. Shahid A, Rana S, Mahmood S, Saeed S. Role of leptin G-2548A polymorphism in age- and gender-specific development of obesity. Journal of biosciences. 2015; 40(3):521–30. Epub 2015/09/04. https://doi.org/10.1007/s12038-014-0435-0; PubMed Central PMCID: PMC449698.

27. Li YX, Zhang Q, Shang XM, Li YQ, Liu XK, Liu CQ, et al. Association of two well-defined polymorphisms in leptin and leptin receptor genes with hypertension and circulating leptin: a meta-analysis. Archives of
28. Marginean CO, Marginean C, Voidazan S, Melit L, Crauciuc A, Duicu C, et al. Correlations Between Leptin Gene Polymorphisms 223 A/G, 1019 G/A, 976 C/A, and Anthropometrical and Biochemical Parameters in Children With Obesity: A Prospective Case-Control Study in a Romanian Population-The Nutrichild Study. Medicine. 2016; 95(12):e3115. Epub 2016/03/26. https://doi.org/10.1097/MD.0000000000003115 PMID: 27015185.

29. Fan SH, Say YH. Leptin and leptin receptor gene polymorphisms and their association with plasma leptin levels and obesity in a multi-ethnic Malaysian suburban population. Journal of physiological anthropology. 2014; 33:15. Epub 2014/06/21. https://doi.org/10.1186/1880-6805-33-15 PMID: 24947733; PubMed Central PMCID: PMCPMC4073586.

30. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 2002; 51(2):536–40. Epub 2002/01/29. PMID: 11812766.

31. Prakash J, Mittal B, Awasthi S, Srivastava N. Association of adiponectin gene polymorphism with adiponectin levels and risk for insulin resistance syndrome. International journal of preventive medicine. 2015; 6:31. Epub 2015/05/08. https://doi.org/10.4103/2008-7802.154773 PMID: 25949781; PubMed Central PMCID: PMCPMC4410438.

32. Menzaghi C, Ercolino T, Di Paola R, Berg AH, Warram JH, Scherer PE, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes. 2002; 51(7):2306–12. Epub 2002/06/28. PMID: 12086965.

33. Guo X, Saad MF, Langefield CD, Williams AH, Cui J, Taylor KD, et al. Genome-wide linkage of plasma adiponectin reveals a major locus on chromosome 3q distinct from the adiponectin structural gene: the IRAS family study. Diabetologia. 2006; 55(6):1723–30. Epub 2006/05/30. https://doi.org/10.2337/db05-0428 PMID: 16731835.

34. Roszkowska-Ganczarz M, Bartoszewicz Z, Polosak J, Kurylowicz A, Jonas M, Mossakowska M, et al. Total and high molecular weight adiponectin and level-modifying polymorphisms of ADIPOQ in centenarians. Endokrynologia Polska. 2012; 63(6):439–46. Epub 2013/01/23. PMID: 23339001.

35. Tso AW, Sham PC, Wat NM, Xu A, Cheung BM, Rong R, et al. Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up study. Diabetologia. 2006; 49(8):1806–15. Epub 2006/06/22. https://doi.org/10.1007/s00125-006-0324-2 PMID: 16787899.

36. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Human molecular genetics. 2002; 11(21):2607–14. https://doi.org/10.1093/hmg/11.21.2607 PMID: 12354786.

37. Ong KL, Li M, Tso AW, Xu A, Cherry SS, Sham PC, et al. Association of genetic variants in the adiponectin gene with adiponectin level and hypertension in Hong Kong Chinese. European journal of endocrinology / European Federation of Endocrine Societies. 2010; 163(2):251–7. Epub 2010/06/03. https://doi.org/10.1530/eje-10-0251 PMID: 20516205.

38. Laumen H, Sanigong AD, Heid IM, Hess J, Herder C, Claussnitzer M, et al. Functional Characterization of Promoter Variants of the Adiponectin Gene Complemented by Epidemiological Data. Diabetes. 2009; 58(4):984–91. https://doi.org/10.2337/db07-1646 PMID: 19074982.

39. Slattery ML, Wolff RK, Herrick J, Caan BJ, Potter JD. Leptin and leptin receptor genotypes and colon cancer: gene-gene and gene-lifestyle interactions. International journal of cancer. 2008; 122(7):1611–7. Epub 2007/12/07. https://doi.org/10.1002/ijc.23135 PMID: 18059035; PubMed Central PMCID: PMCPMC2430084.

40. Liu P, Shi H, Huang C, Shu H, Liu R, Yang Y, et al. Association of LEP A19G polymorphism with cancer risk: a systematic review and pooled analysis. Tumor Biology. 2014; 35(8):8133–41. https://doi.org/10.1007/s13277-014-2086-5 PMID: 24845032.

41. Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOQ1) genes and colorectal cancer risk. Jama. 2008; 300(13):1523–31. Epub 2008/10/02. https://doi.org/10.1001/jama.300.13.1523 PMID: 18827209; PubMed Central PMCID: PMCPMC2628475.

42. Liu L, Zhong R, Wei S, Yin JY, Xiang H, Zhou L, et al. Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancer. PloS one. 2011; 6(11):e27301. Epub 2011/11/17. https://doi.org/10.1371/journal.pone.0027301 PMID: 22087284; PubMed Central PMCID: PMCPMC3210156.
43. Guo X, Liu J, You L, Li G, Huang Y, Li Y. Association between adiponectin polymorphisms and the risk of colorectal cancer. Genetic testing and molecular biomarkers. 2015; 19(1):9–13. Epub 2014/12/10. https://doi.org/10.1089/gtmb.2014.0238 PMID: 25489716; PubMed Central PMCID: PMCPMC4278080.

44. Hu X, Feng F, Li X, Yuan P, Luan R, Yan J, et al. Gene polymorphisms related to insulin resistance and gene-environment interaction in colorectal cancer risk. Annals of human biology. 2015; 42(6):560–8. Epub 2015/07/24. https://doi.org/10.3109/03014460.2014.1002532 PMID: 25263767.

45. Al-Harithy RN, Al-Zahrani MH. The adiponectin gene, ADIPOQ, and genetic susceptibility to colon cancer. Oncology letters. 2012; 3(1):176–80. Epub 2012/06/29. https://doi.org/10.3892/ol.2011.443 PMID: 22740876; PubMed Central PMCID: PMCPMC3362502.

46. Ye C, Wang J, Tan S, Zhang J, Li M, Sun P. Meta-analysis of adiponectin polymorphisms and colorectal cancer risk. International journal of medical sciences. 2013; 10(9):1113–20. Epub 2013/07/23. https://doi.org/10.7150/ijms.6843 PMID: 23869187; PubMed Central PMCID: PMCPMC3714387.

47. Ye J, Jiang L, Wu C, Liu A, Mao S, Ge L. Three ADIPOR1 Polymorphisms and Cancer Risk: A Meta-Analysis of Case-Control Studies. PLOS ONE. 2015; 10(6):e0127253. https://doi.org/10.1371/journal.pone.0127253 PMID: 26047008.

48. Organization WH. Obesity: preventing and managing the global epidemic: World Health Organization; 2000.

49. the Haplotype Reference C, McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nature Genetics. 2016; 48:1279. https://doi.org/10.1038/ng.3643 27548312.

50. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006; 38(8):904–9. https://doi.org/10.1038/ng.1847 PMID: 16862161.

51. Calle EE, Thun MJ. Obesity and cancer. Oncogene. 2004; 23(38):6365–78. Epub 2004/08/24. https://doi.org/10.1038/sj.onc.1207751 PMID: 15322511.

52. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995; 57(1):289–300.

53. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and Risk of Colorectal Cancer: A Systematic Review of Prospective Studies. PLOS ONE. 2013; 8(1):e53916. https://doi.org/10.1371/journal.pone.0053916 PMID: 23349764.

54. Cleave MP, Ray A, Rogozina OP, Dogan S, Grossmann ME. Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention. Frontiers in bioscience (Scholar edition). 2009; 1:329–57. Epub 2009/06/02. PMID: 19482706.

55. Marcello MA, Calixto AR, de Almeida JF, Martins MB, Cunha LL, Cavalari CA, et al. Polymorphism in LEP and LEPR May Modify Leptin Levels and Represent Risk Factors for Thyroid Cancer. International journal of endocrinology. 2015; 2015:173218. Epub 2015/03/27. https://doi.org/10.1155/2015/173218 PMID: 25810718; PubMed Central PMCID: PMCPMC4355553.

56. Baumgartner RN, Ross RR, Waters DL, Brooks WM, Morley JE, Montoya GD, et al. Serum leptin in elderly people: associations with sex hormones, insulin, and adipose tissue volumes. Obes Res. 1999; 7(2):141–9. PMID: 10102250.

57. Partida-Perez M, de la Luz Ayala-Madrigal M, Peregrina-Sandoval J, Macias-Gomez N, Moreno-Ortiz J, Leal-Ugarte CE, et al. Association of LEP and ADIPOQ common variants with colorectal cancer in Mexican patients. Cancer biomarkers: section A of Disease markers. 2010; 7(3):117–21. Epub 2011/01/26. https://doi.org/10.3233/cbm-2010-0154 PMID: 21263187.

58. Yi Kyong W, Shin JH, Seo Hong S, Lee Jae K, Oh MJ, Kim T, et al. Role of Estrogen Receptor-α and −β in Regulating Leptin Expression in 3T3-L1 Adipocytes. Obesity. 2012; 16(11):2393–9. https://doi.org/10.1038/oby.2008.389 PMID: 18719660.

59. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. Journal of the National Cancer Institute. 1980; 65(6):1201–7. Epub 1980/12/01. PMID: 7001123.

60. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res. 2000; 60(2):245–8. Epub 2000/02/10. PMID: 10667568.

61. Rudolph A, Toth C, Hoffmeister M, Roth W, Herpel E, Jansen L, et al. Expression of oestrogen receptor β and prognosis of colorectal cancer. British journal of cancer. 2012; 107(5):831–9. https://doi.org/10.1038/bjc.2012.323 PubMed PMID: PMC3425967. PMID: 22828608.
62. Williams C, DiLeo A, Niv Y, Gustafsson JA. Estrogen receptor beta as target for colorectal cancer prevention. Cancer letters. 2016; 372(1):48–56. Epub 2015/12/29. https://doi.org/10.1016/j.canlet.2015.12.009 PMID: 26708506; PubMed Central PMCID: PMCPMC4744541.

63. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995; 83(7):1263–71. Epub 1995/12/29. PMID: 8548812.

64. Shen M, Shi H. Estradiol and Estrogen Receptor Agonists Oppose Oncogenic Actions of Leptin in HepG2 Cells. PLOS ONE. 2016; 11(3):e0151455. https://doi.org/10.1371/journal.pone.0151455 PMID: 26982332

65. Kraus WL, Weis KE, Katzenellenbogen BS. Determinants for the repression of estrogen receptor transcriptional activity by ligand-occupied progestin receptors. The Journal of steroid biochemistry and molecular biology. 1997; 63(4–6):175–88. Epub 1998/02/12. PMID: 9459183.

66. Wang Y, Jacobs EJ, Teras LR, Pavluck AL, Rodriguez C, Thun MJ, et al. Lack of evidence for effect modification by estrogen of association between body mass index and colorectal cancer risk among postmenopausal women. Cancer causes & control: CCC. 2007; 18(8):793–9. Epub 2007/07/10. https://doi.org/10.1007/s10552-007-9009-5 PMID: 17619155.

67. Hoffmeister M, Raum E, Winter J, Chang-Claude J, Brenner H. Hormone replacement therapy, body mass, and the risk of colorectal cancer among postmenopausal women from Germany. British journal of cancer. 2007; 97(11):1486–92. Epub 2007/11/08. https://doi.org/10.1038/sj.bjc.6604066 PMID: 17987040; PubMed Central PMCID: PMCPMC2360268.

68. Adams KF, Leitzmann MF, Albanes D, Kipnis V, Mouw T, Hollenbeck A, et al. Body Mass and Colorectal Cancer Risk in the NIH–AARP Cohort. American Journal of Epidemiology. 2007; 166(1):36–45. https://doi.org/10.1093/aje/kwm049 PMID: 17449892

69. Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut. 2002; 51(2):191–4. PubMed PMID:PMC1773328. PMID: 12117878